Consensus ResMed Inc. Boerse Muenchen

Stocks

RMEA

AU000000RMD6

Advanced Medical Equipment & Technology

Market Closed - Boerse Muenchen 16:43:27 2026-09-30 EDT			5-day change	1st Jan Change
19.80 ^EUR	-.--%		-.--%	-3.88%

09-15	ResMed Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:00 AM
09-15	ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says	MT

c30877d8c.iMKX4w0DluofCY4Ju1yvK49mQk-jACFJAlxxl9QfJNQ.4YOnt3hXrq9wYeJcwT72UvUlGiroRU0ecGQl1ZBUSbnM-uKCOTLziVRt_Q~bf32cac4872563f04e2bf3af5eff71d9

Analysts' recommendations: ResMed Inc.

09-15	ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says	MT
09-15	RBC Upgrades ResMed to Outperform From Sector Perform, Raises Price Target to $262 From $244	MT
09-15	Analyst recommendations: Abercrombie & Fitch, Eli Lilly, Philip Morris, Ulta Beauty…
09-10	Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating	MT
09-03	Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating	MT
08-31	KeyBanc Adjusts Price Target on ResMed to $267 From $255, Keeps Overweight Rating	MT
08-19	Rothschild & Co Redburn Initiates ResMed at Neutral With $230 Price Target	MT
08-07	Jefferies Adjusts Price Target on ResMed to $220 From $225	MT
08-07	Mizuho Adjusts Price Target on ResMed to $235 From $220	MT
08-07	Morgan Stanley Adjusts Price Target on ResMed to $227 From $229	MT
08-07	KeyBanc Capital Adjusts Price Target on ResMed to $255 From $260	MT
08-07	Piper Sandler Adjusts Price Target on ResMed to $225 From $233	MT
08-07	Baird Adjusts Price Target on ResMed to $213 From $217	MT
08-07	Wells Fargo Adjusts Price Target on ResMed to $215 From $225	MT
08-07	RBC Capital Adjusts PT on ResMed to $244 From $234, Maintains Sector Perform Rating	MT
08-07	Analyst recommendations: Micron Technology, Lockheed Martin, Airbnb, Johnson Controls International, The Allstate Corporation…
07-24	BofA Adjusts Price Target on ResMed to $320 From $310	MT
07-21	ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says	MT
07-17	RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276	MT
07-15	Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating	MT
07-14	Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating	MT
07-13	Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270	MT
07-13	Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34	MT
07-10	Jefferies Adjusts Price Target on ResMed to $225 From $240	MT
07-09	Jarden Adjusts ResMed's Price Target to AU$40.20 from AU$42.70, Keeps at Overweight	MT

More recommendations

Other Advanced Medical Equipment & Technology

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	THERMO FISHER SCIENTIFIC, INC.					-3.94%
	DANAHER CORPORATION					+2.81%
	INTUITIVE SURGICAL, INC.					+15.57%
	BOSTON SCIENTIFIC CORPORATION					+39.02%
	EDWARDS LIFESCIENCES CORPORATION					+14.62%
	AGILENT TECHNOLOGIES, INC.					+0.1%
	SIEMENS HEALTHINEERS AG					+17.78%
	VEEVA SYSTEMS INC.					+6.72%
	WATERS CORPORATION					+0.78%
	Average					+10.38%
	Weighted average by Cap.					+7.18%